Powder: -20°C for 3 years | In solvent: -80°C for 1 year
KA2507 is a potent and selective HDAC6 inibitor with an IC50 of 2.5nM.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 18,500 | |||
5 mg | 在庫あり | ¥ 45,500 | |||
10 mg | 在庫あり | ¥ 73,000 | |||
25 mg | 在庫あり | ¥ 123,000 | |||
50 mg | 在庫あり | ¥ 177,500 | |||
100 mg | 在庫あり | ¥ 248,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 7,000 |
説明 | KA2507 is a potent and selective HDAC6 inibitor with an IC50 of 2.5nM. |
ターゲット&IC50 | HDAC6:2.5nm |
In vitro | At concentrations selective for HDAC6 inhibition, KA2507 did not inhibit in vitro proliferation of mouse or human cancer cells. |
In vivo | KA2507 (100-200 mg/kg; p.o.; daily; for 20 days) inhibits tumor growth in the syngeneic B16-F10 mouse melanoma model. KA2507 also demonstrates antitumor efficacy in CT26 and MC38 colorectal cancer models. Analysis of tumor samples also indicates modulation of biomarkers of antitumor immunity at efficacious dosing, with KA2507 administration resulting in reduced STAT3 activation (as measured by phospho-STAT3, an important suppressor of the antitumor immune response), reduced PD-L1 expression, and increased expression of MHC class I. KA2507 exhibits poor oral bioavailability (mice 15%) and Cmax (mice 300 ng/mL) following oral administration (mice 200 mg/kg).[1] |
分子量 | 322.32 |
分子式 | C16H14N6O2 |
CAS No. | 1636894-46-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/mL (186.15 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
KA2507 1636894-46-6 Chromatin/Epigenetic DNA Damage/DNA Repair HDAC KA 2507 modulatory KA-2507 colorectal Histone deacetylases immune cancer antitumor Inhibitor melanoma inhibit inhibitor